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The purpose of this study was to demonstrate that dy- 
namic MRI covering both breasts can provide sensitiv- 
ity for tumor detection as well as specificity and 
sensitivity for differentiation of tumor malignancy. 
Three-dimensional gradient echo scans were used cov- 
ering both breasts. Before Gd-DTPA bolus injection, 
two scans were obtained with different flip angles, and 
after injection, a dynamic series followed. Thirty-two 
patients were scanned according to this protocol. 
From these scans, in addition to enhancement, the 
value of Tl before injection was obtained. This was 
used to estimate the concentration of Gd-DTPA as well 
as the pharmacokinetic parameters governing its time 
course. Signal enhancement in three-dimensional dy- 
namic scanning was shown to be a sensitive basis for 
detection of tumors. In our series, all but two mam- 
mographically snspicious lesions did enhance, and in 
three cases, additional enhancing lesions were found, 
two of which were in the contralateral breast. The 
parameter most suited for classification of breast le- 
sions into benign or malignant was shown to be the 
pharmacokinetically defined permeability kl, which, 
for that test, gave a sensitivity of 92% and a specificity 
of 70%. Our three-dimensional dynamic MRI data are 
sensitive for detection of mammographically occult 
breast tumors and specific for classification of these 
as benign or malignant. 
Index terms: Magnetic resonance imaging * Gd-DTPA - Pharmacokinetics 
Breast lesions 
JMRI 19973 7:702-715 
From the Medisch Spectrum Twente. Department of MRI Research, Haaks- 
bergerstraat 55. 7513 ER Enschede. The Netherlands U.A.B., R.K.K.M.H., 
G.D., P.W.A.A.K., J.H.M.. E.D.P.V); the University ofTwente. Department of 
Electrical Enginecring, Enschede. the Netherlands (J.S., C.H.S.1: and the Re- 
gional Pathology laboratmy. Enschede, the Netherlands IR.A.1.V.). Received 
July 15, 1996; revision requested December 1 6  revision received February 
21, 1997; accepted March 10. Supported by a grant of Philips Medical Sys- 
tems. Part of this work was presented at  the meeting of the Society for Mag- 
netic Resonance Imaging, Dallas, 1994. Address correspondence to  J.A.B., 
Zweerslaan 3. 6591 GN Son. The Netherlands. E-mail: denboer@iaehv.nl. 
0 ISMRM, 1997 
Abbreviations: DClS = ductal carcinoma in situ, FFE = fast field echo, fom 
= figure of merit. Gd-DTPA = gadolinium diethylenetriamine penlaacetic 
acid. NSA = number of signals averaged, ROC = receiver operating charac- 
teristic, R01 = region of interest. 
DIAGNOSIS OF BREAST LESION malignancy usually is 
based on core biopsy guided by x-ray mammography or 
ultrasound. However, there are classes of patients for 
whom such a method is not optimal. This, for example, 
is the case when a lesion is small, multifocal, or not well 
delineated. In such cases, surgical biopsy would be 
needed. For reduction of patient morbidity and financial 
expense, it would be desirable to avoid unnecessary bi- 
opsies by a noninvasive test that is sensitive for lesion 
detection as well as specific for distinction between be- 
nign and malignant. Additionally, such a test could be of 
value for follow-up studies of breast lesions after lum- 
pectomy or chemotherapy. 
Contrast-enhanced MRI may be suitable for these pur- 
poses (1-24). Rapid enhancement of the signal in post- 
contrast images is strongly indicative of the presence of 
a lesion. This can be observed when the scan is repeated 
as a dynamic series (1-10,14-16,19-24). However, there- 
ported specificity for classification of breast lesions as be- 
nign or malignant is not always satisfactory (5,7,10-12). 
In some of the quoted literature (11-16,21), the scan 
methods are aimed at the detection of contrast enhance- 
ment in the complete breast. The scans used by Heywang 
et a1 (111, Harms et al (121, and Perman et al (15) cover 
one entire breast; those of Rigauts (13) cover both 
breasts. In these cases, the MRI examination can be used 
for detection of occult lesions. Sensitivity of the MRI ex- 
amination in this respect is shown to be important be- 
cause of the potential presence of lesion multifocality (12) 
or when lesion location is uncertain (13,15). At high spa- 
tial resolution of 1 x 1 x 5 mm3 Ill) or 1 x 1 x 1 mm3 
(12), lesion detection sensitivity is found to be close to 
100% for cases that already are suspected on the basis 
of x-ray mammography. However, in these last reports, 
the temporal resolution was low (300 seconds per scan) 
and differentiation between benign and malignant was 
not adequately possible. 
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In studies by Perman et a1 (15) and Hulka et al (21), an 
approach is presented in which enhancement is in- 
spected dynamically with a much higher temporal reso- 
lution, 44 seconds (15) and 6 seconds (211, while the 
entire breast is covered at the same time. Such an ap- 
proach is attractive when detection sensitivity as well as 
specificity for tumor classification are both required. To 
reach sufficient temporal resolution, in these reports, a 
three-dimensional scan technique was used with a mod- 
erate spatial resolution (pixel size is 3 x 1 x 2 mm3 in 
one breast (1 5) and 7 X 1.5 X 3 mm3 in both breasts (2 1)). 
In the present study, this approach is used as well and 
our scan is a dynamic scan that covers both breasts with 
a temporal resolution of 30 seconds and spatial resolu- 
tion of 6 X 1.3 X 1.7 mm3. 
A more advanced data analysis is possible (16-24) 
when the enhancement-time courses are converted to 
concentration-time courses, using the precontrast relax- 
ation time T1 (in this report called the native Tl). In such 
an approach, the enhancement is replaced by the con- 
trast medium concentration, thereby removing the influ- 
ence of this tissue property from the data. In the present 
study, accordingly, the native T1 is determined for each 
patient and each enhancement factor is reduced to gad- 
olinium diethylenetriamine pentaacetic acid (Gd-DTPA) 
concentration. 
In addition, in the same reports, the shape of the con- 
centration-time course is modeled as a pharmacokinetic 
curve. In these models, the leakage of the contrast agent 
into the interstitial space is seen as the cause of the sig- 
nal enhancement. Hulka et a1 (21) demonstrated statis- 
tically that the derived pharmacokinetic parameter, when 
compared with signal enhancement, improves the degree 
of separation between malignant and benign breast le- 
sions, but they do not show whether this improvement is 
due to their correction for T1 or to their pharmacokinetic 
modeling. To inspect the potential of this approach, we 
have fitted the dynamic T1 corrected MR data to a phar- 
macokinetic model, derived from that ofTofts et a1 (20,22) 
and obtained model parameters. 
The purpose of our work is to determine the sensitivity 
for tumor detection obtained with our three-dimensional 
dynamic contrast-enhanced MRI scan, given its moderate 
spatial resolution. Next, we want to find the sensitivity 
and specificity for classification of lesions as benign or 
malignant that can be reached with our data and the con- 
tribution of each of the two steps that we have taken in 
data reduction: correction of the enhancement data for 
native T1 and pharmacokinetic curve fitting. 
0 MATERLALS AND METHODS 
Patients 
Thirty-two patients participated in the study on a vol- 
untary basis. These patients were chosen when mam- 
mographic images gave reason to suspect a malignancy, 
and for each patient, the decision already had been made 
that biopsy was needed. The first group of 15 patients 
(age range, 50-70 years; mean age, 57 years) consisted 
of clients from the Dutch mass population screening. In 
this group, only women who had nonpalpable lesions 
were included. The second group of 17 patients (age 
range, 30-80 years: mean age, 53 years) consisted of 
symptomatic patients who presented without previous 
breast tumor treatment and for whom surgical biopsy 
was planned. The study protocol was accepted by the 
Ethical Committee of our institution. The MFU examina- 
tion always was carried out before biopsy, However, this 
result was not permitted to influence the course of the 
patients' treatment. 
X-Ray Mammography and Histology 
All x-ray examinations were performed with a Seno- 
graph 600 I mammography system (CGR, Paris, France), 
using craniocaudal, oblique, and mediolateral views. A 
biopsy was obtained from all mammographically suspi- 
cious lesions. Biopsy locations were guided by the x-ray 
mammographic results. In all cases, the specimen was 
removed surgically. After its entire surface had been 
inked to facilitate microscopic recognition of the surgical 
edges, it was sectioned at 5-mm intervals and of each 
part an x-ray image was taken. These images were used 
during the surgical procedure to confirm that the sus- 
pected tissue was contained in the specimen. Tissue 
blocks for paraffin microscopy sections were then ob- 
tained of all grossly and mammographically suspicious 
areas. 
MRI 
MR images were obtained with a Gyroscan ACS MRI 
system (Philips Medical Systems, Eindhoven, the Neth- 
erlands) operating at 1.5 T. The patients were positioned 
prone with both breasts placed in a recess in a linear 
receive-only surface coil. The coil design restricted mo- 
tion of the breast tissue in the craniocaudal direction. 
After a preliminary scan for localization, all scans were 
made in the axial direction with a field of view of 320 mm. 
For all scans, a spoiled gradient echo method, Tl-en- 
hanced fast field echo (Tl-FFE), and three-dimensional 
encoding were used. For each scan, 36 partitions of 6 mm 
thick and 3-mm overlap (Fourier interpolation) were ob- 
tained. In this way, the scanned volume had a thickness 
of 108 mm and covered all space in the coil recess. The 
phase-encode gradient was left to right, so that the move- 
ment artefact of the heart did not cross the breasts, 
except for the extreme axillary regions. The scan param- 
eters of the first of the T1-FFE scans were as follows: TR/ 
TE = 16/9 msec, flip angle = 4", acquisition matrix nz X 
ny X nx = 18 X 192 X 256; number of signals averaged 
(NSA) = 2. The value of TE was the lowest in-phase value 
obtainable in our system. This scan was made to allow 
calculation of the native relaxation time T1 (see Appendix 
B). The subsequent seven scans were a dynamic series 
with the same scan parameters, except for the flip angle 
(40") and NSA (1). In the dynamic series, the duration of 
each scan was 30 seconds, which was the minimum that 
could be achieved with the number of slices and the ma- 
trix size. A half scan technique and an elliptic coverage 
of the k plane' were used for scan time reduction. The 
half scan technique was used in the k, direction. Within 
each scan, the k, and k, values were changed in linear 
order in a nested loop with the k, values varying in the 
inner loop. This caused the moment at which both k, and 
k, were zero to occur at a time halfway through each 
scan. That moment, 15 seconds after the start of each 
scan, is the one that best characterizes the dynamic sit- 
uation that is described in the image. We will call this 
moment the characteristic time tc of the scan. 
Before the start of the scans, an injection needle was 
inserted in the cubital vein in the right antecubital fossa. 
1 Elliptic coverage of the k space is possible in three-dimensional acquisition 
without visible loss of spatial resolution by removing the combination oflarge 
k, and k, values. The result is a gain in scan time of approximately 22%. 
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A syringe with 7.5 mmol of Gd-DTPA (Magnevist; Scher- 
ing, Berlin, Germany; 15 mll was connected with the nee- 
dle via a 15-ml cannula filled with physiologic saline, This 
setup allowed injection during the dynamic series with- 
out movement of the patient. 
The start times of the dynamic scans were ts = 0, 50, 
80, 140, 210, 280, and 350 seconds. Completion of the 
first scan was the sign for the radiologist to start injec- 
tion. The syringe was emptied into the cannula in ap- 
proximately 5 seconds, and the tube was then flushed 
with 25 ml of saline in another 5 seconds. Therefore, a 
bolus of contrast medium entered the body starting at  5 
seconds after thr end of the first dynamic scan. The 
transport time tt of the contrast medium from the site of 
injection to the breast was estimated to be 15 seconds. 
This equals the mean delay to peak of the digital sub- 
traction angiography signal a s  observed in the carotids in 
intravenously-injected iodine contrast studies (25) (for 
discussion of the error in this estimate, see Appendix D). 
As a result, the nominal arrival time of the bolus coin- 
cided with the start time of the second dynamic scan (ts 
= 50 seconds). This time was taken as  the zero point of 
the pharmacokinetic time scale. On this scale, the char- 
acteristic times of the remainder scans were at: 
t = (ts - 501 + tc = (ts - 35) seconds 
Lesion Detection 
For lesion detection, the two three-dimensional sets of 
preinjection images (small and large flip angle) were pre- 
sented to the radiologist, along with subtraction images 
that were made from the first and the second postinjec- 
tion scan, using the preinjection scan of the dynamic se- 
ries as a mask. Detection of lesions was based on visual 
inspection of these MR images and correlation of the find- 
ings to x-ray mammography. All mammographic suspi- 
cious lesions could be found confidently by visual 
inspection of the images. All slices with visually apparent 
lesions were subjected to numeric analysis. 
The numeric analysis of the MRI data was performed 
on a workstation on each of the slices selected by the 
radiologist. To correct for motion of the patient between 
the scans, when necessary, the images (eight images of 
each slice) were registered with the help of a two-dimen- 
sional shift tool. Shifts were possible in steps as small as 
. 1 times the pixel size. The tool required operator super- 
vision to select the most satisfactory shift. Although sub- 
jective, the process was reproducible within .3 pixels, as 
tested by comparing the shift obtained by two different 
observers. 
Objective and automatic definition of enhancing 
regions was based on comparison of the actual enhance- 
ment-time course of each pixel to a typical reference 
course. To do so, the images of the dynamic scan were 
reduced to a single weighted sum image. The technique 
used for this reduction is derived from eigen image filter- 
ing (26) and discussed in Appendix A. The reference en- 
hancement values are listed in Table A l .  In the weighted 
sum image, the pixel values are high when there is a close 
match between the actual and the reference enhance- 
ment-time course. To define the enhancing region, the 
weighted sum image was thresholded at 75% of its m a -  
imum pixel value. When no supra threshold region re- 
sulted, the threshold was reduced to 50 Yo and, if 
necessary, to 30%. Regions smaller than 8 connected pix- 
els were rejected to avoid misreadings from data that 
were strongly distorted by partial volume effects. 
The sensitivity of detection of the lesions by enhance- 
ment was obtained by comparing the generated enhanc- 
ing regions with the visually ascertained lesions. More- 
over, the enhancing regions were used to define mean 
values for each of the parameters derived per pixel. 
In a few cases with very low enhancement, no enhanc- 
ing region showed up in the automated procedure. Then, 
the lesion was considered to be nonenhancing and, for 
evaluation of mean parameter values, a region of interest 
(ROI) corresponding to the visual area of the lesion was 
defined manually. 
Parameters Obtained per Piwe1 
From the ratio of the two precontrast scans, the relax- 
ation time of the native tissue (Tl,) was calculated with 
help of Equations [Bl] and [BZ] in Appendix B. The scans 
had a constant scale so that all signal values for each 
pixel were directly physically comparable. For each pixel, 
the ratios of the postcontrast and precontrast scans of 
the dynamic series defined six enhancement factors. 
With Equations [Bll and IB31, the Gd-DTPA concentra- 
tions per pixel could be derived from these enhancement 
factors and Tl,. The enhancement factor observed for the 
third dynamic scan [at t = 45 seconds) and the corre- 
sponding concentration were recorded for later use and 
were called Enh(45) and Gd(451. 
A pharmacokinetic model similar to that of Tofts et a1 
(22) was used to describe the time course of the contrast 
medium concentration. The model and its assumptions 
are discussed in Appendix C. Three parameters are ob- 
tained: A, the fractional volume of the vascular space; &, 
that of the leakage space: and k,,, the permeability of the 
boundary between plasma and leakage space. 
The modeled signal enhancement was fitted to the data 
by adjustment of these parameters. This was based on 
minimization of the squared differences between the mod- 
eled and the observed enhancement factors (Levenberg 
Marquardt method). The mean value of the residual 
squared differences, normalized to image noise (see Table 
Dl), was used as  a figure of merit (fom) for the fit. 
Statistical Analysis 
Per enhancing region, a mean value was obtained for 
each of the parameters, Tl,, Enh[45), Gd(45), fL, h, and 
kl, by averaging over all pixels in that region. When more 
than one enhancing region was present in one lesion (the 
lesion was, for example, seen in more than one slice), all 
enhancing regions were analyzed. The parameter values 
belonging to the region with the highest mean were 
used to describe the lesion. Statistical significances of 
these MRI-based lesion parameters were obtained by 
comparing histology. For some of the parameters, re- 
ceiver operating characteristic (ROC) curves and scatter 
diagrams were used to inspect their suitability for lesion 
classification. 
RESULTS 
Figure 1 shows some of the images obtained for a pa- 
tient with a large phyllodes tumor (case 4). Details de- 
scribing how these images were reached are given in the 
legend of this figure. The signal-to-noise ratio in the orig- 
inal MR images (Figs. la, lb ,  and lc) is approximately 
2% of the unenhanced glandular signal. The area of en- 
hancement at 45 seconds (Fig. lc) is rather homogeneous 
and its visual contour has a fair correspondence to that 
selected by our automatic procedure (Figs. lf,  lg, and 
lh). 
Figure 2 shows examples of observed enhancement fac- 
tors as function of time. The enhancement factors shown 
are the mean values per enhancing region. Per case, the 
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Figure 1. Case 4: a 61-year-old patient with a large phyllodes 
tumor. All images are of the same slice: slice 16 of 36. In the 
parameter maps, the gray values are approximately proportional 
to thr values of the parameter mapped. Calipers indicate the rel- 
ative magnification of each image. A n  enhancement-time curve 
for this case is given in Figure 2. (a) Pre bolus scan; T1-FFE; TR 
= 16, TE = 9, flip angle = 4. [b) First scan of the dynamic series. 
before bolus arrival; T1-FFE; TR = 16, TE = 9, flip angle = 40. 
(c) Parameter map of native T1, from images (a) and @). (d) Scan 
at 45 seconds after bolus arrival. The left breast shows an en- 
hancing lesion. (e) Image of enhancement factors at 45 seconds; 
ratio of image (d) and [b); area of the left breast, enlarged. 
e. 
best fitting pharmacokinetic model-based enhancement- 
time curve is drawn for comparison. Two benign cases are 
shown in Figure 2a and two malignant cases are shown 
in Figure 2b. The model parameters and the fom for the 
fit of these curves are given in the figure caption. All 
curves in this figure fit within the error ranges, illustrat- 
ing that our model did give an adequate description of 
the data. The mean fom for all fits (each pixel in the en- 
hancing region, all patients) is 2.6. 
Table 1 lists the demographic, mammographic, histo- 
logic, and MRI data for each patient. All MRI parameters 
are mean values over one enhancing region per lesion 
(the one for which highest mean $, was found). The frac- 
tion of the tumor volume covered by this region was es- 
timated to range from approximately 5% for large tumors 
to more than 50% for small tumors. All data for mam- 
mographically nonsuspicious lesions (no histology avail- 
able) are printed in italics. The cases are arranged in 
order of histologic class and within each class in order of 
increasing In cases 5 and 8, the lesions did not visibly 
enhance in MRI. These lesions could be included for anal- 
ysis after identification on basis of their conspicuity in 
the precontrast images. In case 18, the lesion was situ- 
ated in the axillary region of the breast and part of it was 
in an area that was heavily corrupted because of flow ar- 
tefacts emanating from the heart. In this case, the anal- 
ysis was carried out on a manually defined ROI outside 
the artefact zone. One or more enhancing regions were 
found in 32 of 34 lesions, so that the sensitivity for tumor 
detection on basis of enhancement was 96%. 
Data from Table 1 are summarized in Table 2 (lesions 
for which histology was available), which shows means 
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Figure 1. (Continued). Images (f), (g), and (h) show only the enhancing region visible in (d) but bordered by automatic segmentation 
(see text). (fj Parameter map of vascular space-f, (gray scale: f, = 0...1). lg] Parameter map of leakage space& (gray scale: & = 0...1). 
(h] Parameter map of permeability kZ1 (gray scale: kal = 0...100.10-3 sec-I). 
and SDs of T I ,  Enh(45), Gd(451, fi, f,, and k& taken from 
Table 1 for the groups of benign and malignant cases. For 
comparison, corresponding values are shown for normal 
fat and normal glandular breast tissue. These were ob- 
tained from data of a group of seven normal breasts. Of 
particular interest are the differences of the parameter 
values between benign and malignant lesions. The statis- 
tical significance of these differences was tested with the 
Wilcoxon rank sum test and is given per parameter. Com- 
pared with benign lesions, malignant lesions had a sig- 
nificantly larger mean value of Gd(45), Jl, and kdl. Of 
these, the difference in k1 has the highest significance (P 
< .005), followed by that infi (P < .02). 
In Figure 3, the observed values of Enh(45) and those 
of Isl for each patient are plotted as function of Tl,. 
Enh(45) was correlated significantly to T1, (correlation 
coefficient c = .68; P > 99.9%). Linear regression showed 
that 46% of the variance in Enh(45) can be explained by 
its correlation to TI,. The correlation between kl and T1, 
was much smaller (c = -.35; P < 95%). 
Figure 4 shows ROC curves belonging to tests of tumor 
malignancy with some of the derived lesion parameters. 
In each curve, the true-positive rate is plotted against the 
false-positive rate with the threshold for testing as 
parameter and histology as gold standard. Shown are 
curves for Enh(4.51, Gd(45), and hl. The ROC curve for b1 
shows the largest true-positive rates, followed by the 
curve for Gd(45). 
Figure 5 shows scatter diagrams in which the lesion 
parameters used in Figure 4 are compared with histologic 
diagnosis. In these diagrams, for purpose of illustration, 
malignant in situ and malignant invasive lesions are pre- 
sented as separate classes. Suggested threshold values 
are added to show the results of a tumor malignancy test 
based on each of the diagrams. Using for k,, a threshold 
of 14 * lo-" sec-I, there are three false positives and two 
false negatives, so that for this combination of test 
parameter and threshold, the sensitivity for classification 
of malignant tumors is 92% and the specificity is 70%. 
Inspection of the individual false cases in Table 1 shows 
that one of the false-positive cases is a fibroadenoma and 
the other two are adenosis and adiponecrosis, both char- 
acterized by a low TI and a low enhancement factor. The 
false-negative cases both were comedo-type ductal car- 
cinomas in situ. Figure 5 suggests that the average of 
ductal carcinoma in situ (DCIS) tumors may be different 
from that of invasive tumors, but the difference found 
was not significant. 
Finally, Table 3 shows an overview of enhancing 
regons that did not correlate to mammographically de- 
tected lesions. In case 10, follow-up x-ray mammography 
1 year after lumpectomy of the left breast did not show 
suspicious abnormalities in either breast. In case 11, 
both breasts were resected. In case 27, follow-up x-ray 
mammography 1 year later did not reveal an  abnormality 
in the contralateral (right] breast. 
DISCUSSION 
Quantitative Diagnosis 
From the MR images, we extracted numeric data on 
signal enhancement and used these for diagnostic pur- 
pose. Such a quantitative diagnosis must be objectively 
based. To show how we achieved this, we have @ven a 
detailed account of the steps used in the data analysis. 
Arbitrary choices sometimes had to be made and these 
can influence the parameter values obtained. In this re- 
spect, the representation of the lesions by enhancing 
regions is important. The enhancing regions were se- 
lected by an objective criterion in the fastest enhancing 
part of the lesion. Because of lesion heterogeneity, the 
enhancing regions found in some patients were much 
smaller than the (visually apparent) lesion size. This is in 
line with a remark of Boetes et a1 (181, who discuss oc- 
casional large differences in size between the enhancing 
region and the lesion. 
In the process of reduction of the data to a single di- 
agnostic descriptor per lesion, the representativeness of 
this descriptor should not be lost. Is the enhancingregion 
representative for the lesion as a whole? Gribbestad et a1 
(19) argue that restriction to the maximally enhancing 
region is necessary for a specific diagnosis. We approxi- 
mated this requirement by our definition of the enhanc- 
ing regions and by our choice of reporting the parameter 
values of one enhancing region only. The representative- 
ness of this choice is supported by the observation that 
the parameter values found for different enhancing 
regions belongmg to the same lesion usually were similar. 
Moreover, quantitative diagnostic information must be 
obtained with a sufficiently small measurement error. 
The enhancement factors per pixel have an  accuracy 
about equal to the MR image noise (2%). The concentra- 
tions of Gd-DTPA are less accurate because of the error 
in calculation of T1, (15%) (see Appendix D). An assess- 
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Figure 2. Enhancement data of some cases and fits to these 
data of pharmacokinetic model-based enhancement-time 
curves. (a) Benign lesions. Case 4 (A]: images shown in Figure 
1. Parameters for fit: T1, = 1.695 seconds: f, = ,135, f3 = .31, 
&, = 7.3.  sec-'; fom = .13. Case 3 [V): parameters for fit: 
T1, = 1.02 seconds,f, = .067,S, = .43, b1 = 6.4 X sec-I: 
fom = .41. (b) Malignant lesions. Case 28 [A): parameters for fit: 
T1, = .584 second,f, = .38, f, = .21, Is, = 46 .  10 sec-'; fom 
= . 1 1. Case 24: lesion R- 1 (V): parameters for fit: T1, = .645 
second,f, = .12,& = 64 ,  = 37 X lo-" sec-I: fom = 7.4 Error 
bars indicate the estimated signal inaccuracy per pixel ( ? 2 SD) . 
The fom of the fit in most of these figures is lower betier) than 
that of most fits per pixel, because of noise reduction by aver- 
aging the enhancement values over the HOI. Note that the 
parameters for fit given in the figure captions are not the same 
as those in Table 1. The difference arises because in this figure 
the fit is to the average of the enhancement factors per ROI, 
whereas in Table 1, the fit was obtained per pixel and the values 
given are the averages over the parameter values per pixel. A s  
an example, enhancement values for case 3 are as follows: 
Experimenlal 1.39 1.65 2.01 2.26 2.39 2.45 
According to Table 1 1.43 1.70 2.05 2.27 2.38 2.43 
According to Figure 2a 1.39 1.66 2.02 2.25 2.38 2.45 
ment of the accuracy of the variables obtained with the 
pharmacokinetic model is discussed in Appendix D. The 
most important error sources were identitied as the noise 
in the MR images, the uncertainty in the blood volume 
V, , and the mean transit time of the contrast medium in 
the patient tt. The resulting errors in the pharmacoki- 
netic parameters are summarized in Table D 1. The table 
shows large errors forf, andJd but a relatively small error 
in ka1. Comparison of Table D1 and Table 2 shows that, 
for lesions, the observed distribution infi and& can be 
explained by measurement errors, but even per group of 
lesions, the distribution in T1 and Is, is significantly 
larger than the measurement error. 
The relatively high accuracy of k,, (20%) was reached 
because there was only little propagation to this param- 
eter of the errors in V, and tt [illustrated in Figure C2). 
V, relates to the ordinate scale and tt relates to its offset. 
Where fi and f, are influenced by the ordinate scale and 
its offset, Isl is a measure only of the curvature of the 
enhancement-time curves. 
As a consequence, in our model, relatively accurate b1 
values can be obtained without knowledge of the bolus 
arrival time per patient. Accuracy of kS1 will be preserved 
as long as its value is smaller than ]/At, the inverse of 
the time between the dynamic scans, For A t  = 30 sec- 
onds, this corresponds to Is1 < 33 * sec-I. In our 
series, the mean b, for benign lesions was 15-10-3 sec-' 
and for malignant lesions 35 X lo-, sec (see Table 2). 
The argument shows that the temporal resolution used 
in our dynamic scan was sufficient to resolve in the 
range of interest. 
Tumor Detection 
A first important aspect of our results is that enhance- 
ment, as found in our data, is a reliable detection crite- 
rion for mammographically suspicious lesions with a 
detection sensitivity of 96%. This high sensitivity is rele- 
vant for detection of lesions not found before the MRI ex- 
amination. Table 3 shows that in our series of three 
patients (10% of the cases) eight enhancing regions were 
found that were not suspicious in x-ray mammography. 
These new findings suggest the presence of additional le- 
sions, although no histologic proof of their presence was 
obtained. (At the time of this study, MRI-guided biopsy 
support tools were not available.] Two of the patients with 
new findings entered through the population screening 
program. Moreover, two of the new findings were in the 
contralateral breast. 
We used an  axial slice orientation, which precluded in- 
spection of the extreme axillary regions of the breasts be- 
cause in these areas the images frequently were damaged 
by motion artefacts emanating from the beating heart. As 
an  alternative, we could have used a sagittal scan (as was 
done in refs. 11, 12, and 15), more completely covering a 
single breast and at the same time allowing a smaller field 
of view and, therefore, a higher spatial resolution. Such 
changes in the scan technique potentially could have re- 
vealed smaller and more additional breast lesions but at 
the cost of loosing the coverage of both breasts. 
The minimum lesion size detectable by our data anal- 
ysis method equals the minimum size of the enhancing 
regions below which they are rejected. This size was 8 
pixels, corresponding to a detection limit of about 6 X 6 
x 6 mm3. Scans with higher spatial resolution covering 
both breasts also would have been possible, but only at 
a lower temporal resolution of the dynamic scan. How- 
ever, as discussed above, the temporal resolution used in 
our work is needed to allow assessment of the malig- 
nancy of the breast lesions. Harms and Flamig (12) con- 
cluded that 36% of malignant lesions detected with MRI 
were not found by x-ray mammography. This percentage 
of cases with new findings is higher than we found in our 
series. The reason may be related to the smaller voxel 
used in their study (1 X 1 X 1 mm3), which is likely to 
correspond to a smaller detection limit, but in the cited 
study, the specificity for tumor classification was low. 
Tumor Classification 
The KOC curves of Figure 4 and the scatter diagrams 
of Figure 5 compare the degree of separation of malignant 
and benign lesions that can be obtained from the data. 
Testing of the lesions on Enh(45) is similar to the tests on 
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Table 1 
Demographic, Mammographic, Histologic, and MRI Data per Case 
Client 
of 
Popula- Suspi- Early 
tion cious Enhanc- Enhance- Concen- 
Screen- Lesions, ing ment tration 
Case Age ing Mammog- Lesions, His tologic Histologic at 45 at45 T1, 103. k, 
No. (years) Program raphy M H  Diagnosis Class seconds seconds msec f, (%) (%) (sec-I) 
L1 L1 1,250 16 
L1 _ .  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
48 
68 
62 
61 
51 
42 
44 
56 
67 
43 
57 
63 
53 
49 
50 
35 
49 
50 
55 
32 
67 
51 
61 
44 
64 
57 
51 
70 
60 
80 
68 
59 
0 
0 
1 
1 
1 
0 
0 
0 
1 
0 
0 
1 
0 
1 
1 
0 
1 
0 
1 
0 
0 
0 
1 
0 
1 
1 
1 
0 
1 
0 
1 
0 
Ll 
R1 
R1 
L1 
R1 
L1 
R1 
L1 
L1 
- 
- 
- 
- 
L1 
- 
- 
R1 
R1 
L1 
R1 
L1 
R1 
L1 
L1 
L1 
L1 
L1 
R1 
R1 
R2 
R3 
L1 
L1 
L1 
- 
L1 
L1 
L1 
R1 
R1 
R1 
R1 
- 
R1 
L1 
- 
L1 
L1 
L2 
L3 
L4 
R1 
L1 
R1 
L2 
R1 
R1 
L1 
R1 
L1 
L1 
L1 
L1 
L1 
L1 
L1 
R1 
R1 
R2 
R3 
L1 
L1 
L1 
R1 
L1 
L1 
L1 
R1 
R1 
adenosis 
trauma, fat necrosis 
adenosis 
phyllodes tumour 
fibroadenoma 
(sclerosing) 
fibroadenoma, 
adenosis 
fibroadenoma 
(intracanalicular) 
adiponecrosis 
adenosis 
fibroadenoma 
(pericanalicular) 
DCIS comedo 
ILC 
DCIS comedo 
DCIS comedo 
DCIS comedo 
DCIS comedo 
IDC + DCIS comedo 
(EW 
ILC + LCIS 
DCIS comedo + 
(focal) IDC 
ILC 
IDC 
IDC 
IDC + DCIS 
noncomedo (EIC) 
IDC 
tubulolobular 
carcinoma 
tubulolobular 
carcinoma 
tubulolobular 
carcinoma 
tubular carinoma + 
DCIS non comedo 
DCIS comedo 
LCIS + (multifocal) 
ILC 
IDC 
IDC + DCIS comedo 
IDC 
IDC 
DCIS comedo 
( E m  
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2.16 0.28 
2.19 0.32 
1.69 
2.36 
1.22 
2.29 
3.24 
1.02 
1.4 
3.08 
1.87 
2.22 
2.34 
2.05 
2.34 
2.07 
1.49 
1.42 
2.58 
1.99 
1.85 
2.19 
1.76 
2.87 
2.67 
3.61 
2.57 
2.71 
2.1 
2.47 
2.1 
1.74 
2.12 
2.59 
1.82 
2.1 1 
2.09 
3.01 
2.88 
2.06 
1.54 
0.16 
0.19 
0.54 
0.5 
0.21 
0.05 
0.22 
0.37 
0.31 
0.27 
0.24 
0.39 
0.36 
0.3 
0.17 
0.34 
0.31 
0.34 
0.39 
0.29 
0.29 
0.71 
0.4 
0.37 
0.39 
0.52 
0.38 
0.72 
0.71 
0.55 
0.33 
0.38 
0.49 
0.62 
0.54 
0.46 
0.74 
0.22 
0.62 
64 
967 19 69 
1,083 6 
1,753 17 
976 40 
767 24 
2,629 14 
160 1 
475 7 
1,023 24 
845 15 
1,267 17 
1,405 18 
879 15 
1,029 23 
790 58 
367 16 
525 11 
1,454 24 
778 30 
620 16 
855 36 
729 20 
1,025 46 
1,398 32 
1,948 21 
1,211 34 
889 47 
1,120 3 
628 34 
515 22 
423 28 
908 21 
1,125 35 
455 28 
1,060 12 
594 29 
1,117 14 
7’28 20 
1,176 22 
284 9 
43 
42 
74 
66 
29 
11 
43 
35 
28 
40 
49 
35 
48 
88 
27 
51 
24 
37 
34 
66 
35 
45 
26 
34 
39 
46 
64 
65 
61 
44 
13 
28 
71 
30 
34 
41 
72 
13 
63 
3 
7 
7 
7 
7 
11 
12 
21 
27 
49 
44 
16 
10 
63 
9 
10 
43 
12 
15 
16 
17 
17 
20 
20 
20 
24 
27 
28 
30 
30 
67 
61 
31 
37 
38 
40 
51 
54 
65 
66 
80 
Note.-DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ: IDC, invasive ductal carcinoma: EIC, IDC with extensive 
intraductal component: ILC, invasive lobular carcinoma. Histologic classes: 0 = benign, 1 = malignant. When more lesions were 
found in one patient, they are labeled for the left-sided and right-sided breast as L1, L2.., R1, R2, etc. 
fast enhancement used frequently in the earlier literature 
(1-10). Inspection of the ROC curve for this parameter 
and of the corresponding scatter diagram in Figure 4a 
shows that for our data this approach is not very suc- 
cessful. 
A first cause of the relative lack of specificity in testing 
to Enh(45) is illustrated in Figure B1, which shows from 
theory that this parameter depends on Tl,. This was 
pointed out already by Tofts et a1 (20) and Hulka et a1 
(21). Experimental confirmation of this dependence as a 
strong correlation between these quantities is shown in 
Figure 3a. 
Improved separation can be expected when the data are 
corrected for T1, This correction is obtained by conversion 
of enhancement into Gd-DTPA concentration. The im- 
provement reached is illustrated by the ROC curve for 
Gd(45) in Figure 4 and in the scatter diagram of Figure 5b. 
as a test criterion is suggested by Tofts 
et a1 (20) and by Hulka et a1 (21), who used for the same 
parameter the term “extraction flow product” (EF). Figure 
3b shows that has the required independence of T1,. 
The ROC curve in Figure 4 for testing to and the scat- 
ter diagram in Figure 5c show indeed a further improve- 
ment above that based on M(45). 
The use of 
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I Table 2 I Mean and SDs of Descriptors of Normal Breast Tissue and Lesions, Derived by Analysis of the MRI Data of Table 1 
J3 [%) Is, * lo3 (sec-I) Tissue/Lesion Type Cases T1, (msec) Enh(45) W451 J, (W 
Fat 7 410 2 75 1.06 -C .1 .04 i .02 4 k 2 25 zk 10 13 -C 7 
Benign lesions I Malignant lesions 7 930 % 300 1.25 k .3 .07 i_ .04 2 -I 1 20 T 5 1 2 5  6 I I 10 1110 rt. 650 2.1 F 7 29 +- .15 17 -+ 10 47 19 15 k 13 25 890 t 370 2 3  2 .5 45+-  15 26 2 12 45 2 18 34 L 20 
DiffGence between 
Note.-Numbers given denote mean t SD. 
*Wilcown rank sum test: ns, not significant. 
benign and malignant* ns ns P <  .02 P <  .05 ns P <  ,005 
4 
3.5 
3 
2.5 
2 
1.5 
1 
t v 
100 
80 v t 
0 500 1000 1500 2000 2500 3000 0 500 1000 1500 2000 2500 3000 
Native T1 (msec) Native T1 (msec) 
a. b. 
Figure 3. 
(A) and malignant [A) lesions. (b) Equivalent display, but of kZ1 versus native T1. 
(a) Graphical display of the distribution between patients of enhancement at 45 seconds plotted versus native TI for benign 
The areas under the ROC curves in Figure 4 were com- 
pared statistically in a paired test (2729) and were shown 
to be not significantly different. However, on this scalp, 
the difference between k . ,  and enhancement was almost 
significant (P = .91). 
As a result, k,, is shown to be a powerful test criterion 
for tumor classification. Conditional for the power of the 
test is that a sufficient accuracy is obtained for this 
parameter. In our method, as  discussed above, such an 
accuracy could be obtained without observation of the 
bolus arrival time and with a dynamic scan with a tem- 
poral resolution of 30 seconds. 
Pharmacokinetic analysis of the data should allow a 
direct comparison to the results of other groups obtained 
with similar methods. One of these groups is Huka  et al 
(21), but from their paper, one can derive that in their 
patients, the mean value of EF for benign lesions is 3 - 
sec-I and for malignant lesions 8 .  10 sec This 
is much lower than the values shown in Table 1 for 
(14 and 35 * 10 ., respectively). This difference is sur- 
prising and may be related to a difference in definition of 
the enhancing regions. Hulka et a1 used a threshold for 
EF of 6 - 10-J sec-I. When their threshold is used in Fig- 
ure 5c, no false negatives and five false positives result, 
so that this threshold could be defended as suitable for 
our data (we suggest a threshold of 14 - lo-. sec I ) .  
Hulka et a1 used a scan method with a very high tem- 
poral resolution (6 seconds). Even with their modern echo 
planar scan technique, this was cause for a rather coarse 
spatial resolution (pixel size of 7 X 1.5 X 3 rnm-.]. For 
tumor classification, they noted for their test a sensitivity 
of 86% and a specificity of 93%. When testing with k1 we 
found a similar sensitivity of 92% and a somewhat lower 
specificity of 70%. The difference between the test results 
may be caused by poor statistics because of the small 
series used (Hulka et al: 20 patients; our series: 32 pa- 
tients). 
Considering the obtained test results, the relatively low 
temporal resolution of our scan method seems to be com- 
patible with a high specificity for tumor classification. 
This means that there is opportunity for a scan with a 
high spatial resolution. In our system, we reached a spa- 
tial resolution of 6 X 1.3 X 1.7 mm3. Increased system 
specifications would be desirable in the first place to fur- 
ther improve this spatial resolution. Based on gradient- 
echo techniques, such improvement could be reached 
with stronger gradients allowing a short (in-phase) TE of 
4.5 msec and a short TR. Echo-planar techniques could 
bring a moderate fiirther improvement in resolution, al- 
though determination of T1 by our dual flip angle method 
would not be possible. 
Interpretation of Obtained Parameters 
The pharmacokinetic parameter values found for nor- 
mal tissue and lesions, as shown in Table 2, can be in- 
terpreted, to some extent, as properties of the tissue. This 
is because these parameters have a biophysics definition 
and are independent of the MR technique used. The vol- 
ume fractionsf, andf, of the vascular and leakage space 
compartment in the voxel as defined in the model and 
given in Table 2 can be compared with other data. In nor- 
mal peripheral tissue, the capillary space is 1% (30,31), 
and in adult females, the extracellular water content is 
20% (32). These values are not unlike our values offi and 
f, of normal glandular tissue and fat. 
The values off, in benign as well as malignant lesions are 
higher than those of normal tissue, as shown in Table 2. 
This may be related to tumor-associated angiogenesis 
(9,211. Various literature suggests a contribution to the sig- 
nal enhancement from the vascular residing Gd-DTPA. For 
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False positive fraction 
Figure 4. Receiver operating curves for classification of tumors 
to benign or malignant. Comparison of Enh(45J. Gd(45), and bL 
to histology. 
instance, Boetes et al (18) ascribe the onset of their en- 
hancement-time curves as an arterial contribution to the 
signal. Gilles et al(9) and Hulka et al(21) find a correlation 
between increased capillary density and tumor enhance- 
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ment. Moreover, there is direct evidence that in tumorous 
regions, the size of the vascular space is large, Furman- 
Haran et al (33) show the presence of localized areas of 
dense and permeable capillaries in the tumor in their study 
of MCF-7 human breast tumors implanted in nude mice. In 
addition, they show the enhancement of such areas in dy- 
namic MRI after Gd-DTPA injection. Shweiki et a1 (34) 
conclude that leakage and angiogenesis may occur si- 
multaneously in malignant human tumor tissue. 
Table 2 shows that the values off, found in lesions are 
large a s  well. The combined occurrence of the elevated 
values off, and f, can explain the high detection sensi- 
tivity of contrast-enhanced MRI both for benign and ma- 
lignant breast lesions. 
In conclusion, our data support the notion that malig- 
nant breast tumors are characterized by neovasculari- 
zation and vessel leakage. However, we have no statistical 
evidence regarding whether such properties will depend 
on the histologic type of the tumors that were found in 
our series, nor can we predict the pharmacokinetic be- 
havior of still other types of breast tumors. Neovascular- 
ization in malignant tumors could be specifically de- 
pendent onfi andf,. Our measurement accuracy was not 
sufficient to resolve such a dependence. Improved accu- 
racy for f, and &, could be reached straightforwardly by 
determination of the bolus arrival time per patient, eg, 
with a separate fast two-dimensional scan through the 
0 I A  1B 
Histology 
b. 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
0 1A 1B 
Histology 
Figure 5. Scatter diagrams for classification of lesions in benign and malignant for some test criteria and suggested thresholds 
between these classes. The class of malignant lesions is subdivided into in situ lesions (lA] and invasive lesions (1B). (a) Enhancement 
at 45 seconds: threshold for Enh(45) = 1.7; @) Gd-DTPA concentration at 45 seconds: threshold for Gd(45) = .24 mmol/l. (c) Perme- 
ability; threshold for Is, = 14 * sec-I. 
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Table 3 
Overview of Enhancing Regions not Correspondi 
dons Found in X-Ray Mammography (New Les ios  to 
Case 10 Case 11 Case 27 
ing program 
of mammographi- 
cally suspected 
lesion (see Table 1) 
Hisologic lesion class 0 0 1 
Number of new lesions 4 1 1 
found 
Number of new lesions 3 
with > 14*10-3 
I 1 
I N:zbdr of lesions in 1 0 1 
contralateral breast 
aortic arch. This could potentially result in an additional 
increase of the specificity of the test. 
In our tumor classification tests, one of the false posi- 
tives was the same case of fibroadenoma (case lo), which 
is characterized by a high kS1. Apparently, even after our 
data reduction, fibroadenomas can mimic malignant tu- 
mors and can be expected to create false positives in 
future tests. The false negatives usually included com- 
edo-type ductal carcinoma in situ, of which Gilles et al 
(9) note that angiogenesis sometimes is weak. Figure 5 
suggests that permeability in these tumors may be weak 
as well. Future tests may have false-negative findings for 
such lesions. These remarks indicate that MRI based 
noninvasive testing of breast lesions does not obviate the 
need for histology. 
CONCLUSIONS 
This study shows that our method of scanning, with its 
moderate spatial resolution and moderate temporal res- 
olution, allowed a sensitive detection of tumors in a re- 
gion covering both breasts as well a s  a sensitive and 
specific classification to malignancy of the tumors de- 
tected. The accuracy of classification was shown to be 
improved by removal of the influence of the native T1 
from the data as well as by subsequent phannacokinetic 
modeling. The pharmacokinetic permeability could be 
found with an  acceptable measurement accuracy (20%). 
Based on enhancement, the lesion detection sensitivity 
was 96%. Classification of tumors with was possible 
with a sensitivity of 92% and a specificity of 70%. The 
potential value of the proposed method for detection of 
new malignant tumors not suspicious in x-ray mammog- 
raphy was illustrated by the findings in three patients of 
six new enhancing regions. Five of these had a value of 
The small number of patients tested in this study limits 
its prognostic value. Additional tests are needed to prove 
the clinical value of our approach. Improvement of mea- 
surement accuracy may be needed to find equal or better 
specificity in future series. Such improvements can be re- 
alized. However, the test accuracy obtained in our study 
already indicates that the clinical value of our method for 
patients or clients of population screening with unclear di- 
agnosis or with high risk factors may exist. 
indicating malignant behavior. 
a MPENDIXA 
Derivation of the Weighted Sum Image 
In the dynamic contrast injection studies, contrast en- 
hancement is observable in a number of scans. To em- 
Table A1 
Enhancement Factors and Weighting Factors Used for 
Derivation of the Weighted Sum Images 
Time [seconds) Lesion @I Gland [_) Weighting Factor e 
Expected Enhancement 
0 1 1 - 1.16 
15 2.02 1.06 - .27 
45 2.80 1.15 
95 3.06 1.24 
175 3.05 1.31 
.32 
.39 
.23 
245 3.00 1.32 .14 
315 2.95 1.33 .08 I I 
phasize the enhancement, it can be desirable to have 
access to a single weighted sum image derived from the 
dynamic scans. Weighted summation can be based on 
the comparison of the actually observed enhancement 
factors to their expected values. The method to do this is 
derived from eigen image filtering theory (26). Per pixel, 
the enhancement factors can be considered as an N di- 
mensional vector p, in which N is the number of dynamic 
scans. For the dyiiamic scan described in the main text 
of this report, Table A1 shows the enhancement factors 
expected for a malignant lesion (desired tissue property; 
vector dJ and those expected for normal glandular tissue 
(undesired tissue property; vector 3. These were ob- 
tained by averaging the enhancement observed in five pa- 
tients with malignant lesions (average values of T1: 1,060 
msec; 35 - sec-l; fi: 10%; and f,: 30%) and in 
five regions of normal glandular tissue (parameters from 
Table 2) and smoothing these data. d and u create the 
weighting factors (vector eJ for the weighted summation 
of the enhanced images that maximizes the contrast-to- 
noise ratio between the desired and the undesired tissue 
property vectors. 
The elements of the vector e are listed in Table Al .  For 
each scan, the pixel values c of the composite image are 
calculated with g as: 
- c = e * p  
APPENDIX B 
Conversion of Enhancement to Concentration of Gd- 
DTPA 
For the T1-FFE imaging method, the spoiled gradient- 
echo sequence available on our system, the signal 
strength s is shown theoretically and experimentally ver- 
ified by Van der Meulen et al (35) to be given by: 
(B1) 
s = Mo sin ci (1 - exp(-TR/Tl)) eq(-TE/T2*) 
1 - cos ci exp(-TR/T1) 
When two T1-FFE scans are performed, each with a dif- 
ferent flip angle, as proposed in refs. 16 and 36, the deri- 
vation of T1 is possible from this equation. The value 
obtained is that of T 1 ,  the native value of T1 before admir- 
istration of Gd-DTPA. Rewriting Equation [Bl] shows this 
for signals s, and sp, obtained with flip angles ci and p: 
s, sin p cos CY - sp sin ci cos p 
s, sin p - sp sin CY T1, = TR/ln( 
The change in relaxation time during the dynamic scan 
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Figure B1. Signal enhancement as a function of the tissue c o n  
centration of Gd-DTPA, calculated from Equations [Bl] and [BZ] 
for tissues with different native T1 in a three-dimensional FFE 
sequence with TR = 16, TE = 9, flip angle = 40; r, = 4.5 1 mmol-l 
sec I ;  r.* = 5.5 1 mmol-I sec-I. This figure shows that enhancc- 
ment is an approximately linear function of the concentration 
but, m addition, is almost linearly dependent on native T1. 
is caused by the tissue concentration of Gd-DTPA. Equa- 
tion [B3] is the experimental result taken from Weinmann 
et al (37) and holds over the range of Gd-DTPA concen- 
trations occumng in clinical practice: 0 to 2 mmol/l: 
1 1  
1 1  
- = - + r,C, 
- ~ + ec, 
’ri TI, 
l-2 l-2, 
_ -  
with r, and r,* the relaxivities (1 mmol-I sec-’) and C, the 
average value of concentration of the contrast medium 
taken over all tissue in the voxel (mmol 1 I). When the 
dynamic series starts with a scan before arrival of the 
contrast medium, its concentration can, with the help of 
Equations [B I] and [B3], be found from the enhancement 
factor, if the native T1 is known. 
The overall effect of the influx of contrast medium in 
practical concentrations is an increase in signal intensity 
because of T1 shortening. This relation is illustrated in 
Figure B1. As expected, the enhancement factor is 
roughly proportional to concentration. At much higher 
concentrations, T2* shortening will become dominant 
and the enhancement will saturate. The figure shows, in 
addition, that for a given concentration, the enhancement 
factor is larger when the native T1 is longer. This last 
effect is due to the low signal strength in the precontrast 
images in regions with a long T1. 
APPENDIX C 
Phannacokinetic Model 
The behavior of Gd-DTPA after its injection as a bolus 
into the human body is described as an exchange of 
Gd-DTPA between the compartments shown in Figure 
C1. After its introduction, the contrast medium will dis- 
tribute rapidly in the plasma within the early distribution 
volume V, (38).This volume roughly corresponds to that 
of the plasma in the vascular volume and is loosely re- 
ferred to as “vascular space” in the remainder of this pa- 
per. The concentration in this compartment then drops 
off gradually because of diffusion into the leakage space 
of the body with volume V,. This model is similar to what 
is used in pharmacy to describe the distribution of drugs 
(39). For that reason, the model may be called a ‘‘phar- 
D 
__I 
k 7 0  
4- 
Figure C1. Three-compartment model, used for pharmacoki- 
netic modeling of the concentration of Gd-DTPA as a function of 
time. 
macokinetic model.” For the purpose of analysis, this 
leakage space is thought of as divided into two spatially 
separate compartments, one of which, the voxel leakage 
space (volume VJ, is located in the voxel under consid- 
eration. The compartments exchange Gd-DTPA with 
transfer coefficients Clearing from the vascular com- 
partment via the kidney takes place as  well and has a 
transfer coelficient klo. 
The continuity equations that describe the exchange of 
matter between these compartments for a situation of 
passive concentration driven transport can be expressed 
as equations for the concentrations C,: 
V! v3 
v, v, c, = -k,,C, + kL1 - (C, ~ C,) + k31 - (C, - C,) 
The transfer coefficients k, have the dimension t’ and 
are formally described as the mean permeability surface 
area product per unit volume of Compartment i. Tofts et 
a1 (20) introduced for these coefficients the term “per- 
meability,” which convention we will follow. 
The third term in the first of these equations can be 
neglected because of the very small value of the ratio 
VJV,. When a dose D is injected at  t = 0, C, is assumed 
to step up immediately to its initial value D/V,. Equation 
[C 11 can then be solved. In Figure C2, curves a and b, the 
obtained solutions for C, and C, are shown graphically 
for a typical set of parameters. As can be seen, C, has an 
initial value 1 and an  approximately exponential de- 
crease. C3 starts at zero and shows washin first. After its 
peak concentration has been reached, the washout is at 
a rate that closely follows that of C,. 
Within a voxel, vascular space as  well as leakage space 
will always be present and each will occupy a fraction of 
the total voxel volume. These fractions will be called fi 
and f,. The average concentration of Gd-DTPA in the 
voxel, C,, is the weighted sum of the concentrations in 
each volume fraction: 
The MR signal is assumed to be a function of C,. This 
is true when there is fast exchange of spins between the 
compartments. Fast between cellular and extracellular 
space is expected (40). It is reasonable as well to assume 
its existence between the capillaries and the vascular 
space, considering the open structure of the capillaries 
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Figure C2. Theoretical concentration-time curves of Gd-DTPA 
after bolus injection. Parameters are: D = 7.5 mmol, V, = 7 5 1, 
V, = 16.6 1 ,  4, = .51 X sec-l, kS1 = 20 + 10 * sec-l..f3 = 
.1. (a) Gd-DTPA concentration in plasma space. (b) Concentra- 
tion in leakage space. (c] through (J: Concentration-time curves 
as would be observed by MRI for a plasma spaceh of 0, 10, 20, 
and 30%. (g] Straight line showing the initial slope of curve d to 
be equal t0f3 . kl. 
in the visceral space (41). Equation [CZ] therefore con- 
nects the physics of MRI to that of pharmacokinetics. 
The modeled behavior of C, is shown in Figure C2 (solid 
curves) for some values off,. The step of C, at t = 0 is 
proportional tof,; its increase then continues, starting at 
a slope Jd - k3,, which reflects the washin into the voxel 
leakage space, until the peak concentration is reached. 
As shown in the figure, the peak in C, is reached earlier 
than that in C,, especially for large .f,. 
The output parameters of the model govern the shape 
of the concentration-time curves. These parameters are 
f,,f,, and ks1. Together with T1, and the actual MRI scan 
parameters, they describe the shape of the enhancement- 
time curve as  well. 
In our use of the model, a number of parameter values 
were assumed from the literature. These values and their 
assumed precision for the in vitro situation in the patient 
are listed in Table C 1. 
For the relaxivities r, and r,* of Gd-DTPA, we have used 
literature values observed by Tofts et a1 (42) in gradient- 
echo experiments in gels at 1.5 T. The parameters \TI, V,, 
bl, and k,,, governing the decay of the plasma concen- 
tration of Gd-DTPA after bolus injection are based on ex- 
perimental observations in plasma samples obtained 
from volunteers. These experiments of Weinmann (39) 
show a biexponential decay of the plasma concentration. 
The resulting values of the transfer coefficients follow 
from a mathematical reformulation. 
APPENDIX D 
Errors in the Parameters Obtained from the 
Pharmacokinetic Model 
The errors in the derived parameters are the result of 
application of the fitting procedure to imperfect input 
data. Therefore, an  estimate of the errors in the input 
parameters has to be given first. Such estimates are dis- 
cussed below and summarized in column 2 of Table D 1. 
An estimate of the resulting output errors can be ob- 
tained by observing the propagation of input errors in the 
fitting procedure for representative sets of input data 
(20). We have applied this manner of error estimation in 
five actual input data sets in which the size of the en- 
hancing regions ranged from 10 to 40 pixels and from 
Table C1 
Assumed Parameter Values of the Pharmacokinetic Model 
Relaxivities of GD- r, = 4.5 1 mol-l sec (42) 
DTPA in tissue r,* = 5.5 1 rnol sec-l (42) 
Vascular space 
Leakage volume else- 
Transfer coefficients k,, = .23.10 sec-l (43) 
= .51.10-3 sec-I (43) 
Transport time of Gd- 
DTPA in the body t t =  15 sec (28) 
l/kg (43) 
where in the body V, = .27 l/kg (43) 
v, = .12 
11 to 44 - sec-I. The input parameters were varied 
individually over their error range and the ranges of the 
resulting output errors are shown in Table D1, columns 
3 through 5. The estimated total error per parameter is 
obtained by quadratic addition of the error terms and is 
given at the bottom row of these columns. 
The following input errors were considered: 
Error in the experimental values of T1. Experimental 
assessment of the accuracy of determination of T1 
with our method (dual flip angle TI-FFE) was obtained 
with help of a phantom with calibrated values of T1 
(43). In the range of T1 values of 200 to 1,000 msec, 
the phantom data were shown to be accurate within 
5%. The clinical situation is less favorable. T1 decay 
may not be monoexponential and, in the large field of 
view used, the transmit coil may not be sufficiently 
homogeneous. A visual impression of the accuracy of 
T1 over the transverse breast images is given in Figure 
lc, a parameter image of T1. T1 of the fat is constant 
over most of the field of view and much better than 
the signal in the unprocessed images la and b. Nev- 
ertheless, the T1 values obtained will be approximate 
only. Their accuracy is expected to be only approxi- 
mately 15%. 
0 Movement of the patient between the dynamic scans 
was corrected by in-plane shifting of the images. After 
reregistration, the remaining in-plane error of move- 
ment was estimated to be less than .3 pixels. The 
movement perpendicular to the imaging plane is esti- 
mated to be less than 2 111111. The error in the data from 
patient movement was considered negligible and is not 
shown. 
Movement of the patient (presumably mainly respira- 
tory motion) during each dynamic scan was cause of a 
slight ghost, visible for instance in the background of 
Figure la. The intensity of the ghost was a few percent 
of the scale maximum. For error analysis, it was as- 
sumed to behave as  random noise. 
Image noise in the MRI data from the dynamic scans. 
The range of the thermal noise per pixel was observed 
to be smaller than 1% (2/.655 times the SD in a ghost- 
free background image region, compared with the scale 
maximum). Ghost and thermal noise together were es- 
timated to have a range of 2% of the scale maximum. 
Intravoxel inhomogeneity was not observed directly. 
For small enhancing regions, partial volume effects 
during the dynamic scans can become an important 
reason for intravoxel inhomogeneity, which then may 
degrade the meaning of the parameter estimates. The 
restriction that was imposed for the minimum size of 
the enhancing region (eight pixels) reduces this influ- 
ence of partial volume effects. The error caused by in- 
travoxel inhomogeneity was estimated by increasing 
the voxel size in the test data sets with a factor of 2 
and repeating the analysis. 
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Table D1 
Error Sources and Error Propagation to Output Param- 
eters 
Error Range 
Error Sources [2 SD) 
TIN +/-15% 
Image noise +/-2% 
Intra-voxel inhomoge- x2 
VL + / -20% 
rl +/-20% 
r2* + / - 50% 
v 2  +/-20% + / - 20% 
+ / -20% 41 k10 
ti i /- 10 seconds 
neity 
Output Parameter 
Error Per 
Source (%] 
9 12 2 
6 14 14 
6 7 8  
20 20 0 
fl .f; k,, 
20 20 0 
5 5 0  
9 9 0  
9 9 0  
9 9 0  
32 22 12 
Total error in output 45% 41% 20% 
parameters 12 SD): 
The value for pharmacokinetic input parameters V,, rl, 
rz*, V,, bl, and k,, were assumed to be accurate within 
20% with the exception of r2*, which is likely to be less 
accurate (441, so we assumed 50% accuracy for that 
parameter. 
The range of transport times tt of the contrast medium 
from the place of injection to the breast was estimated 
from the data of Kruger (25) to be 15 ? 10 seconds. 
These data show, in addition, that the front edge of the 
bolus is not a step function but has a rise time of ap- 
proximately 6 seconds. The influence of this finite rise 
time on the analysis was neglected in comparison with 
the temporal resolution of the dynamic scan (30 sec- 
onds). 
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